COVID Clinical Trial
Official title:
Prospective Observational Study Evaluating the Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopic Procedures (DECORE Study)
The aim of our study to compare the proportion of patients who develop SARS-CoV-2 disease in 3 groups: patients undergoing a abdominal ultrasound examination in a Specialty Center, patients undergoing endoscopic procedure in a third level hospital with CoronaVirus Disease (COVID-19) hospitalization plants and patients who make a telephonic visit (do not go to the hospital) in the digestive system service.
Patients will undergo a telephonic interview 48-96h before the procedure where will ask about
the presence of symptoms suggestive of SARS-CoV-2 infection. Optionally, they will also be
carried out a scan (PCR) to detect infection 48-96h before procedure, withdrawing from the
study patients with positive PCR or infection suspected by clinical data according to the
questionnaire, after evaluating the responses to the questionnaire by one of the members of
the research team.
Endoscopic examinations will be carried out according to the recommendations of the Spanish
Society for Digestive Endoscopy (SEED). The patient will perform a hand wash with solution
hydroalcoholic before entering the endoscopy room, and you will be placed a surgical mask and
gloves. Staff close to the patient will carry FFP2 mask, exceptionally surgical mask, gown
(waterproof in high-risk examinations as established in the SEED guidelines), hat, nitrile
gloves and face shield or safety glasses (reusable) and shim covers. The examinations will be
carried out using sedation guided by endoscopist according to current clinical guidelines.
Ultrasonographic examinations (US) will be carried out according to clinical guideline. The
examinator will wear a filtering face pieces 2 (FFP2) mask, exceptionally surgical mask,
gown, cap, nitrile gloves and face shield or goggles safety (reusable) and shoe covers. The
gel bottle, the transducer and the gurney will be washed before each US with low level
disinfectant.
Patients who meet the inclusion criteria and do not have any exclusion criteria will be
invited to participate in the study. The patients who agree to participate will complete the
informed consent according to the law 41/2002 of patient autonomy without for that reason
alter the relationship with your doctor or cause any harm to your treatment. The monitoring
period will have a maximum duration of 17 days. It will consist of a telephone control
through a pre-established checklist. In case of any positive answer to the questionnaire, it
will be completed the study through the consultation of the investigators by means of a
polymerase chain reaction (PCR).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |